MedTrace Logo

ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI)

NCT06813664 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-22

No results posted yet for this study

Summary

This is an open-label, prospective single arm Phase II trial that investigates the role of ablative stereotactic body radiation therapy (SBRT) in oncogene driven metastatic non-small cell lung cancer (mNSCLC) patients with oligoprogressive disease (OPD) on targeted therapy (TKI) followed by circulating tumor DNA (ctDNA) analysis for tailoring targeted therapies.

Conditions

  • Metastatic NSCLC - Non-Small Cell Lung Cancer
  • OligoProgressive Metastatic Disease

Interventions

RADIATION

Radiotherapy

SBRT/high-dose radiotherapy Standard of care targeted therapy

RADIATION

Radiotherapy

SBRT/high-dose radiotherapy Second-line targeted therapy

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2028-04-01
Completion
2028-04-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06813664 on ClinicalTrials.gov